Syngene International Invests in Peptide Laboratory and Advanced Automation
Syngene International has set up a dedicated peptide laboratory equipped with advanced automation technologies to accelerate hit-to-lead timelines. The investment enhances the company’s integrated drug discovery and development capabilities, reinforcing its position as a leading partner for end-to-end research solutions.
Direct-to-Biology (D2B) Workflows | 16/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy